CA2098738A1 - Controlled Release Oxycodone Compositions - Google Patents

Controlled Release Oxycodone Compositions

Info

Publication number
CA2098738A1
CA2098738A1 CA2098738A CA2098738A CA2098738A1 CA 2098738 A1 CA2098738 A1 CA 2098738A1 CA 2098738 A CA2098738 A CA 2098738A CA 2098738 A CA2098738 A CA 2098738A CA 2098738 A1 CA2098738 A1 CA 2098738A1
Authority
CA
Canada
Prior art keywords
oxycodone
mean
controlled release
hours
ng
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA2098738A
Other languages
French (fr)
Other versions
CA2098738C (en
Inventor
Benjamin Oshlack
Mark Chasin
John Joseph Minogue
Robert Francis Kaiko
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Purdue Pharma LP
Original Assignee
Benjamin Oshlack
Mark Chasin
John Joseph Minogue
Robert Francis Kaiko
Euroceltique S.A.
Purdue Pharma L.P.
Mundipharma Laboratories Gmbh
Purdue Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
Priority to US800,549 priority Critical
Priority to US07/800,549 priority patent/US5266331A/en
Application filed by Benjamin Oshlack, Mark Chasin, John Joseph Minogue, Robert Francis Kaiko, Euroceltique S.A., Purdue Pharma L.P., Mundipharma Laboratories Gmbh, Purdue Pharma filed Critical Benjamin Oshlack
Priority to PCT/US1992/010146 priority patent/WO1993010765A1/en
Publication of CA2098738A1 publication Critical patent/CA2098738A1/en
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25178688&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2098738(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Publication of CA2098738C publication Critical patent/CA2098738C/en
Application granted granted Critical
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/485Morphinan derivatives, e.g. morphine, codeine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2027Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/5015Organic compounds, e.g. fats, sugars
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids

Abstract

A method for substantially reducing the range in daily dosages required to control pain in approximately 80 % of patients is disclosed whereby an oral solid controlled release dosage formulation having from about 10 to about 40 mg of oxycodone or a salt thereof is administered to a patient. The formulation provides a mean maximum plasma concentration of oxycodone from about 6 to about 60 ng/ml from a mean of about 2 to about 4.5 hours after administration, and a mean minimum plasma concentration from about 3 to about 30 ng/ml from about 10 to about 14 hours after repeated "q12h" (i.e.) every 12 hours) administration through steady-state conditions. Another embodiment is directed to a method for substantially reducing the range in daily dosages required to control pain in substantially all patients. The figure is a graph showing the mean plasma oxycodone concentration for a 10 mg controlled release oxycodone formulation prepared in accordance with the present invention and a study reference standard.
CA002098738A 1991-11-27 1992-11-25 Controlled release oxycodone compositions Expired - Lifetime CA2098738C (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US800,549 1991-11-27
US07/800,549 US5266331A (en) 1991-11-27 1991-11-27 Controlled release oxycodone compositions
PCT/US1992/010146 WO1993010765A1 (en) 1991-11-27 1992-11-25 Controlled release oxycodone compositions

Publications (2)

Publication Number Publication Date
CA2098738A1 true CA2098738A1 (en) 1993-05-28
CA2098738C CA2098738C (en) 1999-08-17

Family

ID=25178688

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002098738A Expired - Lifetime CA2098738C (en) 1991-11-27 1992-11-25 Controlled release oxycodone compositions

Country Status (30)

Country Link
US (13) US5266331A (en)
EP (15) EP2340833A3 (en)
JP (2) JP3375960B2 (en)
CN (2) CN1245958C (en)
AT (9) AT454150T (en)
AU (1) AU657027B2 (en)
BG (1) BG61753B1 (en)
BR (1) BR9205498A (en)
CA (1) CA2098738C (en)
CZ (4) CZ298499B6 (en)
DE (10) DE69233691T2 (en)
DK (10) DK1325746T3 (en)
ES (9) ES2268189T3 (en)
FI (5) FI113152B (en)
GR (1) GR3022273T3 (en)
HK (6) HK1068004A1 (en)
HU (10) HU227518B1 (en)
IL (1) IL103909A (en)
MX (1) MX9302968A (en)
NO (6) NO307028B3 (en)
PH (1) PH31679A (en)
PL (2) PL172236B1 (en)
PT (8) PT1438959E (en)
RO (1) RO115112B1 (en)
RS (3) RS50054B (en)
RU (1) RU2122411C1 (en)
SK (1) SK280295B6 (en)
WO (1) WO1993010765A1 (en)
YU (1) YU49495B (en)
ZA (1) ZA9209227B (en)

Families Citing this family (280)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5656295A (en) * 1991-11-27 1997-08-12 Euro-Celtique, S.A. Controlled release oxycodone compositions
US20070275062A1 (en) * 1993-06-18 2007-11-29 Benjamin Oshlack Controlled release oxycodone compositions
US20080075781A1 (en) * 1992-11-25 2008-03-27 Purdue Pharma Lp Controlled release oxycodone compositions
US5266331A (en) * 1991-11-27 1993-11-30 Euroceltique, S.A. Controlled release oxycodone compositions
US7740881B1 (en) 1993-07-01 2010-06-22 Purdue Pharma Lp Method of treating humans with opioid formulations having extended controlled release
US5681585A (en) 1991-12-24 1997-10-28 Euro-Celtique, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US5958459A (en) * 1991-12-24 1999-09-28 Purdue Pharma L.P. Opioid formulations having extended controlled released
US5968551A (en) * 1991-12-24 1999-10-19 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
US5580578A (en) * 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
IL109460A (en) 1993-05-10 1998-03-10 Euro Celtique Sa Controlled release formulation comprising tramadol
US5849240A (en) * 1993-11-23 1998-12-15 Euro-Celtique, S.A. Method of preparing sustained release pharmaceutical compositions
US5891471A (en) * 1993-11-23 1999-04-06 Euro-Celtique, S.A. Pharmaceutical multiparticulates
IL110014A (en) * 1993-07-01 1999-11-30 Euro Celtique Sa Solid controlled-release oral dosage forms of opioid analgesics
US5879705A (en) * 1993-07-27 1999-03-09 Euro-Celtique S.A. Sustained release compositions of morphine and a method of preparing pharmaceutical compositions
EP1442745A1 (en) * 1993-10-07 2004-08-04 Euro-Celtique Orally administrable opioid formulations having extended duration of effect
US5478577A (en) * 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
US5843480A (en) * 1994-03-14 1998-12-01 Euro-Celtique, S.A. Controlled release diamorphine formulation
US6210714B1 (en) * 1993-11-23 2001-04-03 Euro-Celtique S.A. Immediate release tablet cores of acetaminophen having sustained-release coating
GB9422154D0 (en) 1994-11-03 1994-12-21 Euro Celtique Sa Pharmaceutical compositions and method of producing the same
US5965161A (en) * 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
US5558879A (en) * 1995-04-28 1996-09-24 Andrx Pharmaceuticals, Inc. Controlled release formulation for water soluble drugs in which a passageway is formed in situ
GB9519363D0 (en) 1995-09-22 1995-11-22 Euro Celtique Sa Pharmaceutical formulation
US5811126A (en) * 1995-10-02 1998-09-22 Euro-Celtique, S.A. Controlled release matrix for pharmaceuticals
CN100475210C (en) * 1996-03-08 2009-04-08 尼科梅德丹麦有限公司 Modified release multiple-units dosage composition
AU3404997A (en) * 1996-05-31 1998-01-05 Euro-Celtique S.A. Sustained release oxycodone formulations with no fed/fast effect
JPH1050306A (en) * 1996-07-31 1998-02-20 Toyota Autom Loom Works Ltd Manufacture of hydrogen storage alloy electrode
DE19710008A1 (en) * 1997-03-12 1998-09-17 Basf Ag Solid, at least two-phase formulations of a sustained-release opioid analgesic
RS49982B (en) * 1997-09-17 2008-09-29 Euro-Celtique S.A., Synergistic analgesic combination of opioid analgesic and cyclooxygenase-2 inhibitor
NZ505192A (en) * 1997-12-22 2003-05-30 Euro Celtique S A method of preventing abuse of opioid dosage forms , whereby opioid agonist and opioid antagonist are only extractable together
EP1685839B8 (en) 1997-12-22 2013-06-26 Euro-Celtique S.A. Pharmaceutical oral dosage form comprising a combination of an opioid agonist and opioid antagonist
US6375957B1 (en) 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
IL128818D0 (en) * 1998-03-12 2000-01-31 Akzo Nobel Nv Making dosage units using low shear granulation
EP0955048A1 (en) * 1998-03-12 1999-11-10 Akzo Nobel N.V. Making dosage units using low shear granulation
US20020006438A1 (en) * 1998-09-25 2002-01-17 Benjamin Oshlack Sustained release hydromorphone formulations exhibiting bimodal characteristics
US6806294B2 (en) 1998-10-15 2004-10-19 Euro-Celtique S.A. Opioid analgesic
US8545880B2 (en) * 1999-02-26 2013-10-01 Andrx Pharmaceuticals, Llc Controlled release oral dosage form
DE19918325A1 (en) 1999-04-22 2000-10-26 Euro Celtique Sa Extruded drug dosage form, e.g. granulate for tableting, comprising an active agent in a polysaccharide-containing matrix, giving a release profile which is controllable by extrusion conditions and/or the inclusion of additives
PT1623703E (en) 1999-10-29 2012-01-09 Euro Celtique Sa Controlled release hydrocodone formulations
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
SK287105B6 (en) * 1999-12-20 2009-12-07 Schering Corporation Bilayer sustained release oral dosage composition
WO2001045668A2 (en) * 1999-12-20 2001-06-28 Schering Corporation Stable extended release oral dosage composition comprising pseudoephedrine and desloratadine
AP1665A (en) 2000-02-08 2006-09-22 Euro Celtique Sa Tamper-resistant oral opioid agonist formulations.
KR101045144B1 (en) 2000-10-30 2011-06-30 유로-셀티크 소시에떼 아노뉨 Sustained Release Hydrocodone Formulations
US20110104214A1 (en) 2004-04-15 2011-05-05 Purdue Pharma L.P. Once-a-day oxycodone formulations
KR20060028821A (en) 2001-05-02 2006-04-03 유로-셀티크 소시에떼 아노뉨 Once-a-day oxycodone formulations
WO2002092060A1 (en) 2001-05-11 2002-11-21 Endo Pharmaceuticals, Inc. Abuse-resistant controlled-release opioid dosage form
CA2449519A1 (en) * 2001-06-08 2002-12-19 Endo Pharmaceuticals, Inc. Controlled release dosage forms using acrylic polymer, and process for making the same
US8329216B2 (en) 2001-07-06 2012-12-11 Endo Pharmaceuticals Inc. Oxymorphone controlled release formulations
DK1404331T3 (en) * 2001-07-06 2008-01-28 Penwest Pharmaceuticals Co Sustained release formulations of oxymorphone
CN1610551A (en) * 2001-07-06 2005-04-27 恩德制药公司 Parenteral administration of 6-hydroxy-oxymorphone for use as an analgesic
WO2003007802A2 (en) 2001-07-18 2003-01-30 Euro-Celtique, S.A. Pharmaceutical combinations of oxycodone and naloxone
JP4504013B2 (en) 2001-08-06 2010-07-14 ユーロ−セルティーク エス.エイ. Opioid agonist formulations having releasable and sequestered antagonists
US20030068375A1 (en) 2001-08-06 2003-04-10 Curtis Wright Pharmaceutical formulation containing gelling agent
US20030044458A1 (en) 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
WO2003013433A2 (en) 2001-08-06 2003-02-20 Euro-Celtique S.A. Sequestered antagonist formulations
AU2002321879A1 (en) * 2001-08-06 2003-03-03 Thomas Gruber Pharmaceutical formulation containing dye
WO2003024430A1 (en) 2001-09-21 2003-03-27 Egalet A/S Morphine polymer release system
EP2957281A1 (en) 2001-09-21 2015-12-23 Egalet Ltd. Polymer release system
AU2002337686B2 (en) * 2001-09-26 2008-05-15 Penwest Pharmaceuticals Company Opioid formulations having reduced potential for abuse
PE20030527A1 (en) * 2001-10-24 2003-07-26 Gruenenthal Chemie Pharmaceutical formulation with delayed release that contains 3- (3-dimethylamino-1-ethyl-2-methylpropyl) phenol or a pharmaceutically acceptable salt of the same and tablets for oral administration which contain
PT1484056E (en) * 2002-02-21 2013-10-14 Otsuka Pharma Co Ltd Sustained release preparations and process for producing the same
US7666876B2 (en) * 2002-03-19 2010-02-23 Vernalis (R&D) Limited Buprenorphine formulations for intranasal delivery
JP4620355B2 (en) * 2002-04-05 2011-01-26 ユーロ−セルティーク エス.エイ. Matrix for sustained, constant and independent release of active compounds
BR0309620A (en) * 2002-04-29 2005-03-15 Alza Corp Methods and dosage forms for controlled release of oxycodone
US20050106249A1 (en) * 2002-04-29 2005-05-19 Stephen Hwang Once-a-day, oral, controlled-release, oxycodone dosage forms
KR20050034645A (en) * 2002-05-31 2005-04-14 알자 코포레이션 Dosage forms and compositions for osmotic delivery of variable dosages of oxycodone
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
US20040001889A1 (en) 2002-06-25 2004-01-01 Guohua Chen Short duration depot formulations
US10668060B2 (en) 2009-12-10 2020-06-02 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
US10004729B2 (en) 2002-07-05 2018-06-26 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
WO2004004693A1 (en) * 2002-07-05 2004-01-15 Collgegium Pharmaceutical Abuse-deterrent pharmaceutical compositions of opiods and other drugs
US8557291B2 (en) 2002-07-05 2013-10-15 Collegium Pharmaceutical, Inc. Abuse-deterrent pharmaceutical compositions of opioids and other drugs
US8840928B2 (en) 2002-07-05 2014-09-23 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
US20040058946A1 (en) * 2002-07-05 2004-03-25 Buchwald Stephen L. Abuse-resistant prodrugs of oxycodone and other pharmaceuticals
US7168140B2 (en) * 2002-08-08 2007-01-30 Milliken & Company Flame resistant fabrics with improved aesthetics and comfort, and method of making same
AU2003258280A1 (en) * 2002-08-15 2004-03-03 Noramco, Inc. Oxycodone-hydrochloride polymorhs
CA2498798A1 (en) * 2002-09-20 2004-04-01 Alpharma, Inc. Sustained-release opioid formulations and methods of use
DK1551372T3 (en) 2002-09-20 2018-07-23 Alpharma Pharmaceuticals Llc Sequeration substances and related compositions and procedures
US20040110781A1 (en) * 2002-12-05 2004-06-10 Harmon Troy M. Pharmaceutical compositions containing indistinguishable drug components
US9107804B2 (en) 2002-12-10 2015-08-18 Nortec Development Associates, Inc. Method of preparing biologically active formulations
AU2003299659A1 (en) 2002-12-13 2004-07-09 Durect Corporation Oral drug delivery system comprising high viscosity liquid carrier materials
GB0300531D0 (en) 2003-01-10 2003-02-12 West Pharm Serv Drug Res Ltd Pharmaceutical compositions
US7230005B2 (en) * 2003-03-13 2007-06-12 Controlled Chemicals, Inc. Compounds and methods for lowering the abuse potential and extending the duration of action of a drug
EP1782834A3 (en) * 2003-03-13 2007-08-01 Controlled Chemicals, Inc. Oxycodone conjugates with lower abuse potential and extended duration of action
DE602004031096D1 (en) 2003-03-26 2011-03-03 Egalet As Morphine system with controlled release
US20040202717A1 (en) 2003-04-08 2004-10-14 Mehta Atul M. Abuse-resistant oral dosage forms and method of use thereof
WO2004093819A2 (en) 2003-04-21 2004-11-04 Euro-Celtique, S.A. Tamper resistant dosage form comprising co-extruded, adverse agent particles and process of making same
MY135852A (en) 2003-04-21 2008-07-31 Euro Celtique Sa Pharmaceutical products
US8158149B2 (en) * 2004-05-12 2012-04-17 Chelsea Therapeutics, Inc. Threo-DOPS controlled release formulation
US20060105036A1 (en) 2003-05-12 2006-05-18 Stephen Peroutka Threo-dops controlled release formulation
US20060165790A1 (en) * 2003-06-27 2006-07-27 Malcolm Walden Multiparticulates
TWI357815B (en) * 2003-06-27 2012-02-11 Euro Celtique Sa Multiparticulates
SI2279729T1 (en) * 2003-07-17 2016-10-28 Banner Life Sciences, LLC Controlled release preparations
US8075872B2 (en) 2003-08-06 2011-12-13 Gruenenthal Gmbh Abuse-proofed dosage form
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
DE10336400A1 (en) 2003-08-06 2005-03-24 Grünenthal GmbH Anti-abuse dosage form
DK1842533T3 (en) * 2003-08-06 2013-05-27 Gruenenthal Gmbh Method of administration secured against abuse
US20050053659A1 (en) * 2003-09-10 2005-03-10 Pace Gary W. Methods and compositions for reducing the risk associated with the administration of opioid analgesics in patients with diagnosed or undiagnosed respiratory illness
EP1677768A4 (en) * 2003-10-03 2011-06-29 Elite Lab Inc Extended release formulations of opioids and method of use thereof
US7201920B2 (en) 2003-11-26 2007-04-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of opioid containing dosage forms
US20070269505A1 (en) * 2003-12-09 2007-11-22 Flath Robert P Tamper Resistant Co-Extruded Dosage Form Containing An Active Agent And An Adverse Agent And Process Of Making Same
US8883204B2 (en) 2003-12-09 2014-11-11 Purdue Pharma L.P. Tamper resistant co-extruded dosage form containing an active agent and an adverse agent and process of making same
DE10361596A1 (en) * 2003-12-24 2005-09-29 Grünenthal GmbH Process for producing an anti-abuse dosage form
TWI350762B (en) 2004-02-12 2011-10-21 Euro Celtique Sa Particulates
EP1771160A2 (en) 2005-01-28 2007-04-11 Euroceltique S.A. Alcohol resistant dosage forms
GB0403098D0 (en) 2004-02-12 2004-03-17 Euro Celtique Sa Extrusion
AT419836T (en) * 2004-03-30 2009-01-15 Euro Celtique Sa Manipulation safe dosing form with an adsorben and an adverse medium
TWI365880B (en) * 2004-03-30 2012-06-11 Euro Celtique Sa Process for preparing oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone and oxycodone hydrochloride composition,pharmaceutical dosage form,sustained release oeal dosage form and pharmaceutically acceptable package having less than 25 pp
US20050226929A1 (en) * 2004-04-12 2005-10-13 Jianbo Xie Controlled release opioid analgesic formulation
DE102004020220A1 (en) * 2004-04-22 2005-11-10 Grünenthal GmbH Process for the preparation of a secured against misuse, solid dosage form
EP1604667A1 (en) * 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioids for the treatment of the restless leg syndrome
EP1604666A1 (en) 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD)
CA2569961A1 (en) * 2004-06-10 2005-12-29 Glatt Air Techniques, Inc Controlled release pharmaceutical formulation
LT1765292T (en) 2004-06-12 2018-01-10 Collegium Pharmaceutical, Inc. Abuse-deterrent drug formulations
DE102004032103A1 (en) * 2004-07-01 2006-01-19 Grünenthal GmbH Anti-abuse, oral dosage form
DE102004032049A1 (en) * 2004-07-01 2006-01-19 Grünenthal GmbH Anti-abuse, oral dosage form
GB2418854B (en) 2004-08-31 2009-12-23 Euro Celtique Sa Multiparticulates
CA2578540A1 (en) 2004-09-01 2006-03-16 Euro-Celtique S.A. Opioid dosage forms having dose proportional steady state cave and auc and less than dose proportional single dose cmax
AT537844T (en) 2004-09-17 2012-01-15 Durect Corp Permanent local anesthetic composition with saib
US20080152595A1 (en) * 2004-11-24 2008-06-26 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of orally administered pharmaceutical products
MX2007007836A (en) 2004-12-27 2007-08-20 Eisai R&D Man Co Ltd Method for stabilizing anti-dementia drug.
US20090208579A1 (en) * 2004-12-27 2009-08-20 Eisai R & D Management Co., Ltd. Matrix Type Sustained-Release Preparation Containing Basic Drug or Salt Thereof, and Method for Manufacturing the Same
US20060280789A1 (en) * 2004-12-27 2006-12-14 Eisai Research Institute Sustained release formulations
DE102005005449A1 (en) * 2005-02-04 2006-08-10 Grünenthal GmbH Process for producing an anti-abuse dosage form
DE102005005446A1 (en) * 2005-02-04 2006-08-10 Grünenthal GmbH Break-resistant dosage forms with sustained release
EP1702558A1 (en) 2005-02-28 2006-09-20 Euro-Celtique S.A. Method and device for the assessment of bowel function
EP1695700A1 (en) * 2005-02-28 2006-08-30 Euro-Celtique S.A. Dosage form containing oxycodone and naloxone
JP5095615B2 (en) 2005-06-27 2012-12-12 バリアント・インターナショナル・(バルバドス)・ソサイアティーズ・ウィズ・リストリクティッド・ライアビリティValent International (Barbados) S.R.L. Modified release of bupropion salt
CN1957909B (en) * 2005-10-31 2013-09-11 阿尔扎公司 Methods of reducing alcohol-induced dose dumping for opioid sustained release oral dosage forms
PL116330U1 (en) * 2005-10-31 2007-04-02 Alza Corp Method for the reduction of alcohol provoked rapid increase in the released dose of the orally administered opioide with prolonged liberation
EP1849460A3 (en) * 2005-10-31 2007-11-14 ALZA Corporation Methods of reducing alcohol-induced dose dumping for opioid sustained release oral dosage forms
US20100172989A1 (en) * 2006-01-21 2010-07-08 Abbott Laboratories Abuse resistant melt extruded formulation having reduced alcohol interaction
US20090317355A1 (en) * 2006-01-21 2009-12-24 Abbott Gmbh & Co. Kg, Abuse resistant melt extruded formulation having reduced alcohol interaction
CA2882048C (en) 2006-02-03 2020-03-24 Proventiv Therapeutics, Llc Treating vitamin d insufficiency and deficiency with 25-hydroxyvitamin d2 and 25-hydroxyvitamin d3
US20070212414A1 (en) * 2006-03-08 2007-09-13 Penwest Pharmaceuticals Co. Ethanol-resistant sustained release formulations
CN101400731A (en) * 2006-03-15 2009-04-01 城北化学工业株式会社 Stabilized polyolefin resin and method of stabilizing polyolefin resin
US20070281016A1 (en) * 2006-06-06 2007-12-06 Endo Pharmaceuticals Inc., A Delaware Corporation Sustained release oxycodone composition with acrylic polymer and surfactant
US20070281017A1 (en) * 2006-06-06 2007-12-06 Endo Pharmaceuticals Inc., A Delaware Corporation Sustained release oxycodone composition with acrylic polymer and metal hydroxide
BRPI0714039A2 (en) 2006-06-19 2014-12-23 Alpharma Inc Pharmaceutical composition
EP2679228B1 (en) 2006-06-21 2018-03-21 Opko Ireland Global Holdings, Ltd. Therapy using vitamin D repletion agent and vitamin D hormone replacement agent
ZA200900640B (en) * 2006-08-04 2010-06-30 Ethypharm Sa Granule and orally disintegrating tablet comprising oxycodone
JP2010501011A (en) * 2006-08-16 2010-01-14 オースペックス・ファーマシューティカルズ・インコーポレイテッドAuspex Pharmaceuticals, Inc. Preparation and benefits of opioid analgesics
SA2709B1 (en) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. Tamper Resistant Oral Pharmaceutical Dosage Forms Comprising an Opioid Analgesic
US20080069891A1 (en) 2006-09-15 2008-03-20 Cima Labs, Inc. Abuse resistant drug formulation
WO2009035474A1 (en) * 2007-09-13 2009-03-19 Cima Labs Inc. Abuse resistant drug formulation
US8445018B2 (en) 2006-09-15 2013-05-21 Cima Labs Inc. Abuse resistant drug formulation
PL2124556T3 (en) 2006-10-09 2015-02-27 Charleston Laboratories Inc Pharmaceutical compositions
PT2117521E (en) 2006-11-03 2012-09-10 Durect Corp Transdermal delivery systems comprising bupivacaine
DE102007011485A1 (en) 2007-03-07 2008-09-11 Grünenthal GmbH Dosage form with more difficult abuse
EP3542792A1 (en) 2007-04-25 2019-09-25 Opko Ireland Global Holdings, Ltd. Controlled release 25-hydroxyvitamin d
US8202542B1 (en) 2007-05-31 2012-06-19 Tris Pharma Abuse resistant opioid drug-ion exchange resin complexes having hybrid coatings
AU2008258596B2 (en) 2007-06-04 2013-02-14 Egalet Ltd Controlled release pharmaceutical compositions for prolonged effect
US20080318993A1 (en) * 2007-06-21 2008-12-25 Endo Pharmaceuticals, Inc. Method of Treating Pain Utilizing Controlled Release Oxymorphone Pharmaceutical Compositions and Instruction on Dosing for Hepatic Impairment
US20080318994A1 (en) 2007-06-21 2008-12-25 Endo Pharmaceuticals, Inc. Method of Treating Pain Utilizing Controlled Release Oxymorphone Pharmaceutical Compositions and Instruction on Dosing for Renal Impairment
US20090124650A1 (en) * 2007-06-21 2009-05-14 Endo Pharmaceuticals, Inc. Method of Treating Pain Utilizing Controlled Release Oxymorphone Pharmaceutical Compositions and Instructions on Effects of Alcohol
US20090022798A1 (en) * 2007-07-20 2009-01-22 Abbott Gmbh & Co. Kg Formulations of nonopioid and confined opioid analgesics
RS51313B (en) 2007-11-09 2010-12-31 Acino Pharma Ag.51311 Retard tablets with hydromorphon
AU2008347158B8 (en) 2007-12-06 2013-08-22 Durect Corporation Oral pharmaceutical dosage forms
AU2008346870A1 (en) * 2007-12-17 2009-07-16 Alpharma Pharmaceuticals, Llc Pharmaceutical composition
US8623418B2 (en) 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
EP3090743A1 (en) 2008-01-09 2016-11-09 Charleston Laboratories, Inc. Pharmaceutical compositions for treating headache and eliminating nausea
KR101616246B1 (en) 2008-01-25 2016-05-02 그뤼넨탈 게엠베하 Pharmaceutical dosage form
US20090246276A1 (en) 2008-01-28 2009-10-01 Graham Jackson Pharmaceutical Compositions
US9226907B2 (en) 2008-02-01 2016-01-05 Abbvie Inc. Extended release hydrocodone acetaminophen and related methods and uses thereof
KR101094231B1 (en) 2008-02-18 2011-12-14 하나제약 주식회사 Sustained release solid formulations and methods of manufacturing the same
MX2010009990A (en) 2008-03-11 2010-12-15 Depomed Inc Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic.
US8372432B2 (en) 2008-03-11 2013-02-12 Depomed, Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
ES2593356T3 (en) 2008-04-02 2016-12-07 Opko Ireland Global Holdings, Ltd. Useful methods, compositions, uses and kits for vitamin D deficiency and related disorders
US9282927B2 (en) 2008-04-24 2016-03-15 Invention Science Fund I, Llc Methods and systems for modifying bioactive agent use
US20100063368A1 (en) * 2008-04-24 2010-03-11 Searete Llc, A Limited Liability Corporation Computational system and method for memory modification
US20090271375A1 (en) * 2008-04-24 2009-10-29 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Combination treatment selection methods and systems
US20100022820A1 (en) * 2008-04-24 2010-01-28 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational system and method for memory modification
US20090312668A1 (en) * 2008-04-24 2009-12-17 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational system and method for memory modification
US20100076249A1 (en) * 2008-04-24 2010-03-25 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational system and method for memory modification
US20100100036A1 (en) * 2008-04-24 2010-04-22 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational System and Method for Memory Modification
US20100081861A1 (en) * 2008-04-24 2010-04-01 Searete Llc Computational System and Method for Memory Modification
US9662391B2 (en) * 2008-04-24 2017-05-30 The Invention Science Fund I Llc Side effect ameliorating combination therapeutic products and systems
US20090271122A1 (en) * 2008-04-24 2009-10-29 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Methods and systems for monitoring and modifying a combination treatment
US20100125561A1 (en) * 2008-04-24 2010-05-20 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational system and method for memory modification
US20100041958A1 (en) * 2008-04-24 2010-02-18 Searete Llc Computational system and method for memory modification
US9064036B2 (en) * 2008-04-24 2015-06-23 The Invention Science Fund I, Llc Methods and systems for monitoring bioactive agent use
US20100017001A1 (en) * 2008-04-24 2010-01-21 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational system and method for memory modification
US20090271347A1 (en) * 2008-04-24 2009-10-29 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Methods and systems for monitoring bioactive agent use
US9649469B2 (en) * 2008-04-24 2017-05-16 The Invention Science Fund I Llc Methods and systems for presenting a combination treatment
US20100041964A1 (en) * 2008-04-24 2010-02-18 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Methods and systems for monitoring and modifying a combination treatment
US20100042578A1 (en) * 2008-04-24 2010-02-18 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational system and method for memory modification
US9560967B2 (en) * 2008-04-24 2017-02-07 The Invention Science Fund I Llc Systems and apparatus for measuring a bioactive agent effect
US9026369B2 (en) * 2008-04-24 2015-05-05 The Invention Science Fund I, Llc Methods and systems for presenting a combination treatment
US20090270694A1 (en) * 2008-04-24 2009-10-29 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Methods and systems for monitoring and modifying a combination treatment
US9239906B2 (en) * 2008-04-24 2016-01-19 The Invention Science Fund I, Llc Combination treatment selection methods and systems
US20090312595A1 (en) * 2008-04-24 2009-12-17 Searete Llc, A Limited Liability Corporation Of The State Of Delaware System and method for memory modification
US20100280332A1 (en) * 2008-04-24 2010-11-04 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Methods and systems for monitoring bioactive agent use
US20100130811A1 (en) * 2008-04-24 2010-05-27 Searete Llc Computational system and method for memory modification
US9449150B2 (en) 2008-04-24 2016-09-20 The Invention Science Fund I, Llc Combination treatment selection methods and systems
US8930208B2 (en) * 2008-04-24 2015-01-06 The Invention Science Fund I, Llc Methods and systems for detecting a bioactive agent effect
US20100081860A1 (en) * 2008-04-24 2010-04-01 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational System and Method for Memory Modification
US20090269329A1 (en) * 2008-04-24 2009-10-29 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Combination Therapeutic products and systems
US20090270688A1 (en) * 2008-04-24 2009-10-29 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Methods and systems for presenting a combination treatment
US20090271009A1 (en) * 2008-04-24 2009-10-29 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Combination treatment modification methods and systems
US20100004762A1 (en) * 2008-04-24 2010-01-07 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational system and method for memory modification
US20100069724A1 (en) * 2008-04-24 2010-03-18 Searete Llc Computational system and method for memory modification
US8876688B2 (en) * 2008-04-24 2014-11-04 The Invention Science Fund I, Llc Combination treatment modification methods and systems
EP2273983B1 (en) 2008-05-09 2016-07-20 Grünenthal GmbH Process for the preparation of an intermediate powder formulation and a final solid dosage form under usage of a spray congealing step
WO2009143209A1 (en) * 2008-05-20 2009-11-26 Qrxpharma Limited Dual opioid pain therapy
ES2635733T3 (en) * 2008-07-07 2017-10-04 Euro-Celtique S.A. Use of opioid antagonists to treat urinary retention
US20100260844A1 (en) 2008-11-03 2010-10-14 Scicinski Jan J Oral pharmaceutical dosage forms
US20100151014A1 (en) * 2008-12-16 2010-06-17 Alpharma Pharmaceuticals, Llc Pharmaceutical composition
EP2393484A1 (en) 2009-02-06 2011-12-14 Egalet Ltd. Immediate release composition resistant to abuse by intake of alcohol
WO2010099508A1 (en) 2009-02-26 2010-09-02 Theraquest Biosciences, Inc. Extended release oral pharmaceutical compositions of 3-hydroxy-n-methylmorphinan and method of use
BRPI1006186A2 (en) 2009-03-10 2016-08-23 Euro Celtique Sa immediate release pharmaceutical compositions comprising oxycodone and naloxone
US8811578B2 (en) * 2009-03-23 2014-08-19 Telemanager Technologies, Inc. System and method for providing local interactive voice response services
CA2766179A1 (en) 2009-06-24 2010-12-29 Egalet Ltd. Controlled release formulations
WO2011006012A1 (en) 2009-07-08 2011-01-13 Charleston Laboratories Inc. Pharmaceutical compositions
US20110020451A1 (en) 2009-07-22 2011-01-27 Grunenthal Gmbh Tamper-resistant dosage form for oxidation-sensitive opioids
PL2456427T3 (en) 2009-07-22 2015-07-31 Gruenenthal Gmbh Hot-melt extruded controlled release dosage form
US20110046173A1 (en) * 2009-08-24 2011-02-24 Warren Charles Stern Combination analgesic opioid pain therapy
RU2012112552A (en) * 2009-08-31 2013-10-10 Дипомед, Инк. Pharmaceutical compositions remained in the stomach for immediate and long release of acetaminophene
EP2488029B1 (en) 2009-09-30 2016-03-23 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse
US20110104272A1 (en) * 2009-11-05 2011-05-05 Depomed, Inc. Gastric retentive extended-release dosage forms comprising combinations of acetaminophen and phenylephrine
US8597681B2 (en) 2009-12-22 2013-12-03 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
US9198861B2 (en) 2009-12-22 2015-12-01 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
WO2011095314A2 (en) * 2010-02-03 2011-08-11 Grünenthal GmbH Preparation of a powdery pharmaceutical composition by means of an extruder
AU2013204592A1 (en) * 2012-04-09 2013-10-24 QRxPharma Ltd. Controlled release formulations of opioids
MX339408B (en) * 2010-03-09 2016-05-24 Alkermes Pharma Ireland Ltd Alcohol resistant enteric pharmaceutical compositions.
US8927025B2 (en) 2010-05-11 2015-01-06 Cima Labs Inc. Alcohol-resistant metoprolol-containing extended-release oral dosage forms
CA2801620A1 (en) 2010-07-06 2012-01-12 Gruenenthal Gmbh Novel gastro-retentive dosage forms comprising a gaba analog and an opioid
CA2808219C (en) 2010-09-02 2019-05-14 Gruenenthal Gmbh Tamper resistant dosage form comprising inorganic salt
BR112013005234A2 (en) 2010-09-02 2016-05-03 Grünenthal GmbH Tamper resistant dosage form comprising an anionic polymer.
ES2444591T3 (en) 2010-10-28 2014-02-25 Acino Pharma Ag Medication with the active substance hydromorphone with improved storage stability
UA114887C2 (en) 2010-12-22 2017-08-28 Пюрдю Фарма Л.П. Encased tamper resistant controlled release dosage forms
CN103327969A (en) 2010-12-23 2013-09-25 普渡制药公司 Tamper resistant solid oral dosage forms
CA2824835A1 (en) 2011-02-02 2012-08-09 Alpharma Pharmaceuticals, Llc Pharmaceutical composition comprising opioid agonist and sequestered antagonist
US8927010B2 (en) 2011-03-23 2015-01-06 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US10292937B2 (en) 2011-03-23 2019-05-21 Ironshore Pharmaceuticals & Development, Inc. Methods of treatment of attention deficit hyperactivity disorder
CN103608004A (en) 2011-03-23 2014-02-26 艾伦索尔医药发展股份有限公司 Methods and compositions for treatment of attention deficit disorder
US8916588B2 (en) 2011-03-23 2014-12-23 Ironshore Pharmaceuticals & Development, Inc. Methods for treatment of attention deficit hyperactivity disorder
US9119809B2 (en) 2011-03-23 2015-09-01 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US9603809B2 (en) 2011-03-23 2017-03-28 Ironshore Pharmaceuticals & Development, Inc. Methods of treatment of attention deficit hyperactivity disorder
US9283214B2 (en) 2011-03-23 2016-03-15 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US9498447B2 (en) 2011-03-23 2016-11-22 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US8858963B1 (en) 2011-05-17 2014-10-14 Mallinckrodt Llc Tamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia
US9050335B1 (en) 2011-05-17 2015-06-09 Mallinckrodt Llc Pharmaceutical compositions for extended release of oxycodone and acetaminophen resulting in a quick onset and prolonged period of analgesia
US8741885B1 (en) 2011-05-17 2014-06-03 Mallinckrodt Llc Gastric retentive extended release pharmaceutical compositions
PT2726064T (en) 2011-06-30 2016-12-28 Develco Pharma Schweiz Ag Controlled release oral dosage form comprising oxycodone
PT2736495T (en) 2011-07-29 2017-11-30 Grünenthal GmbH Tamper-resistant tablet providing immediate drug release
MX356421B (en) 2012-02-28 2018-05-29 Gruenenthal Gmbh Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer.
SG10201803195PA (en) 2012-04-17 2018-05-30 Purdue Pharma Lp Systems and methods for treating an opioid-induced adverse pharmacodynamic response
TR201815502T4 (en) 2012-04-18 2018-11-21 Gruenenthal Gmbh Or tamper-resistant and resistant to dose pharmaceutical dosage form of discharges.
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
KR20150059167A (en) 2012-07-06 2015-05-29 에갈렛 리미티드 Abuse deterrent pharmaceutical compositions for controlled release
US9730885B2 (en) 2012-07-12 2017-08-15 Mallinckrodt Llc Extended release, abuse deterrent pharmaceutical compositions
US9101636B2 (en) 2012-11-30 2015-08-11 Acura Pharmaceuticals, Inc. Methods and compositions for self-regulated release of active pharmaceutical ingredient
AP201508579A0 (en) 2013-02-05 2015-07-31 Purdue Pharma Lp Tamper resistant pharmaceutical formulations
KR101847947B1 (en) 2013-03-15 2018-05-28 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 Stabilized modified release vitamin d formulation
CN105120659A (en) 2013-03-15 2015-12-02 度瑞公司 Compositions with a rheological modifier to reduce dissolution variability
US20140271896A1 (en) 2013-03-15 2014-09-18 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
WO2014191396A1 (en) 2013-05-29 2014-12-04 Grünenthal GmbH Tamper resistant dosage form with bimodal release profile
MX2015016112A (en) 2013-05-29 2016-03-31 Grünenthal GmbH Tamper-resistant dosage form containing one or more particles.
EA032465B1 (en) 2013-07-12 2019-05-31 Грюненталь Гмбх Tamper-resistant oral pharmaceutical dosage form containing ethylene-vinyl acetate polymer and process for the production thereof
CN105517551A (en) 2013-07-23 2016-04-20 欧洲凯尔特公司 A combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
CA3042642A1 (en) 2013-08-12 2015-02-19 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
WO2015065547A1 (en) 2013-10-31 2015-05-07 Cima Labs Inc. Immediate release abuse-deterrent granulated dosage forms
WO2015078891A1 (en) 2013-11-26 2015-06-04 Farmaceutici Formenti S.P.A. Preparation of a powdery pharmaceutical composition by means of cryo-milling
WO2015095391A1 (en) 2013-12-17 2015-06-25 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
WO2015145459A1 (en) 2014-03-26 2015-10-01 Sun Pharma Advanced Research Company Ltd. Abuse deterrent immediate release coated reservoir solid dosage form
MX2016014738A (en) 2014-05-12 2017-03-06 Grünenthal GmbH Tamper resistant immediate release capsule formulation comprising tapentadol.
EP3148512A1 (en) 2014-05-26 2017-04-05 Grünenthal GmbH Multiparticles safeguarded against ethanolic dose-dumping
TW201946931A (en) 2014-06-27 2019-12-16 美商C2N醫療診斷有限責任公司 Humanized anti-TAU antibodies
WO2016010771A1 (en) 2014-07-17 2016-01-21 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
US20180085381A1 (en) 2014-08-07 2018-03-29 Opko Ireland Global Holdings, Ltd. Adjunctive Therapy With 25-Hydroxyvitamin D
US9849124B2 (en) 2014-10-17 2017-12-26 Purdue Pharma L.P. Systems and methods for treating an opioid-induced adverse pharmacodynamic response
CA2936741C (en) 2014-10-31 2018-11-06 Purdue Pharma Methods and compositions particularly for treatment of attention deficit disorder
CN107889459A (en) 2015-04-24 2018-04-06 格吕伦塔尔有限公司 Tamper resistant dosage form with release immediately and to solvent-extracted resistance
US9943513B1 (en) 2015-10-07 2018-04-17 Banner Life Sciences Llc Opioid abuse deterrent dosage forms
US10179109B2 (en) 2016-03-04 2019-01-15 Charleston Laboratories, Inc. Pharmaceutical compositions comprising 5HT receptor agonist and antiemetic particulates
US10335405B1 (en) 2016-05-04 2019-07-02 Patheon Softgels, Inc. Non-burst releasing pharmaceutical composition
US9737530B1 (en) 2016-06-23 2017-08-22 Collegium Pharmaceutical, Inc. Process of making stable abuse-deterrent oral formulations
US10335375B2 (en) 2017-05-30 2019-07-02 Patheon Softgels, Inc. Anti-overingestion abuse deterrent compositions
AU2018360383A1 (en) 2017-11-02 2020-05-21 Natureceuticals Sdn. Bhd. Extract of orthosiphon stamineus, formulations, and uses thereof

Family Cites Families (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US291883A (en) * 1884-01-15 Faucet
US2738303A (en) * 1952-07-18 1956-03-13 Smith Kline French Lab Sympathomimetic preparation
US2921883A (en) * 1957-05-03 1960-01-19 Smith Kline French Lab Novel coating material for medicaments
NL263733A (en) * 1960-04-19 1900-01-01
US4132753A (en) * 1965-02-12 1979-01-02 American Cyanamid Company Process for preparing oral sustained release granules
US3458622A (en) * 1967-04-07 1969-07-29 Squibb & Sons Inc Controlled release tablet
US3492397A (en) * 1967-04-07 1970-01-27 Warner Lambert Pharmaceutical Sustained release dosage in the pellet form and process thereof
US3634584A (en) * 1969-02-13 1972-01-11 American Home Prod Sustained action dosage form
US3870790A (en) * 1970-01-22 1975-03-11 Forest Laboratories Solid pharmaceutical formulations containing hydroxypropyl methyl cellulose
GB1405088A (en) 1971-06-03 1975-09-03 Mundipharma Ag Slow release formulation
US3773920A (en) * 1971-07-14 1973-11-20 Nikken Chemicals Co Ltd Sustained release medicinal composition
US3965256A (en) * 1972-05-16 1976-06-22 Synergistics Slow release pharmaceutical compositions
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) * 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US3922339A (en) * 1974-06-20 1975-11-25 Kv Pharm Co Sustained release medicant
GB1478759A (en) * 1974-11-18 1977-07-06 Alza Corp Process for forming outlet passageways in pills using a laser
US3946899A (en) * 1975-02-07 1976-03-30 Allain Charles V Sugar cane planter
JPS5612614B2 (en) * 1978-09-04 1981-03-23
WO1980000659A1 (en) * 1978-10-02 1980-04-17 Purdue Research Foundation Food and pharmaceutical coating composition,method of preparation and products so coated
DE2950977C2 (en) * 1978-12-22 1987-11-05 Elan Corp. P.L.C., Athlone, County Westmeath, Ie
FI63335B (en) * 1979-02-02 1983-02-28 Orion Yhtymae Oy Faring reference for a tabletter with a light light of an effective
US4259314A (en) * 1979-12-10 1981-03-31 Hans Lowey Method and composition for the preparation of controlled long-acting pharmaceuticals
DE3024416C2 (en) * 1980-06-28 1982-04-15 Goedecke Ag, 1000 Berlin, De
US4464378A (en) * 1981-04-28 1984-08-07 University Of Kentucky Research Foundation Method of administering narcotic antagonists and analgesics and novel dosage forms containing same
DE3126703A1 (en) * 1981-07-07 1983-01-27 Thomae Gmbh Dr K Bromhexin retard form and method for their production
US4377568A (en) * 1981-08-12 1983-03-22 Merck Sharp & Dohme (I.A.) Corp. Preparation of aqueous alcoholic dispersions of pH sensitive polymers and plasticizing agents and a method of enteric coating dosage forms using same
US4369172A (en) * 1981-12-18 1983-01-18 Forest Laboratories Inc. Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose
DE3208791A1 (en) * 1982-03-11 1983-09-22 Roehm Gmbh Method for coating medicinal products by means of a coating agent dispersed in water
US4389393B1 (en) * 1982-03-26 1985-10-22
US4443428A (en) * 1982-06-21 1984-04-17 Euroceltique, S.A. Extended action controlled release compositions
DE3314003A1 (en) * 1983-04-18 1984-10-18 Boehringer Ingelheim Kg Divisible tablet with delayed active substance release and method for the production thereof
US4548990A (en) * 1983-08-15 1985-10-22 Ciba-Geigy Corporation Crosslinked, porous polymers for controlled drug delivery
US4629621A (en) * 1984-07-23 1986-12-16 Zetachron, Inc. Erodible matrix for sustained release bioactive composition
US4894234A (en) * 1984-10-05 1990-01-16 Sharma Shri C Novel drug delivery system for antiarrhythmics
JPS636588B2 (en) * 1984-12-27 1988-02-10 Nippon Ekisho Kk
US4600645A (en) * 1985-01-31 1986-07-15 Warner-Lambert Company Process for treating dosage forms
NL8500724A (en) * 1985-03-13 1986-10-01 Univ Groningen Devices for regular release of active substances and method of manufacture thereof
EP0204951B1 (en) * 1985-05-13 1993-01-20 Miles Inc. Use of calcium channel blockers in the production of compositions for withdrawal symptoms
GB8519310D0 (en) * 1985-07-31 1985-09-04 Zyma Sa Granular active substances
GB8521350D0 (en) * 1985-08-28 1985-10-02 Euro Celtique Sa Analgesic composition
GB8613689D0 (en) * 1986-06-05 1986-07-09 Euro Celtique Sa Pharmaceutical composition
GB8613688D0 (en) * 1986-06-05 1986-07-09 Euro Celtique Sa Pharmaceutical composition
EP0249347B1 (en) 1986-06-10 1994-06-29 Euroceltique S.A. Controlled release dihydrocodeine composition
US4861598A (en) * 1986-07-18 1989-08-29 Euroceltique, S.A. Controlled release bases for pharmaceuticals
US4970075A (en) 1986-07-18 1990-11-13 Euroceltique, S.A. Controlled release bases for pharmaceuticals
GB8626098D0 (en) * 1986-10-31 1986-12-03 Euro Celtique Sa Controlled release hydromorphone composition
US5026560A (en) * 1987-01-29 1991-06-25 Takeda Chemical Industries, Ltd. Spherical granules having core and their production
US5266311A (en) * 1987-05-28 1993-11-30 Immunex Corporation Bovine interleukin-1α
US5219575A (en) * 1987-06-26 1993-06-15 Duphar International Research B.V. Compositions with controlled zero-order delivery rate and method of preparing these compositions
DE3721721C1 (en) * 1987-07-01 1988-06-09 Hoechst Ag Process for coating granules
US5068110A (en) * 1987-09-29 1991-11-26 Warner-Lambert Company Stabilization of enteric coated dosage form
US4862598A (en) * 1987-10-01 1989-09-05 Perceptron, Inc. Quick connect/disconnect repeatable sensor mounting apparatus
US5019397A (en) * 1988-04-21 1991-05-28 Alza Corporation Aqueous emulsion for pharmaceutical dosage form
US5024842A (en) * 1988-04-28 1991-06-18 Alza Corporation Annealed coats
JPH01287019A (en) * 1988-05-12 1989-11-17 Tanabe Seiyaku Co Ltd Slowly releasing drug preparation
JP2681373B2 (en) * 1988-07-18 1997-11-26 塩野義製薬株式会社 Method for manufacturing sustained-release preparation
JP2850376B2 (en) * 1988-08-02 1999-01-27 日産化学工業株式会社 Anticancer drug efficacy enhancer
US4983730A (en) * 1988-09-02 1991-01-08 Hoechst Celanese Corporation Water soluble cellulose acetate composition having improved processability and tensile properties
US5178868A (en) * 1988-10-26 1993-01-12 Kabi Pharmacia Aktiebolaq Dosage form
US5202128A (en) * 1989-01-06 1993-04-13 F. H. Faulding & Co. Limited Sustained release pharmaceutical composition
US5330766A (en) * 1989-01-06 1994-07-19 F. H. Faulding & Co. Limited Sustained release pharmaceutical composition
US5196203A (en) * 1989-01-06 1993-03-23 F. H. Faulding & Co. Limited Theophylline dosage form
US5007790A (en) * 1989-04-11 1991-04-16 Depomed Systems, Inc. Sustained-release oral drug dosage form
US5126145A (en) * 1989-04-13 1992-06-30 Upsher Smith Laboratories Inc Controlled release tablet containing water soluble medicament
US5133974A (en) * 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US5122384A (en) * 1989-05-05 1992-06-16 Kv Pharmaceutical Company Oral once-per-day organic nitrate formulation which does not induce tolerance
FR2648020B1 (en) * 1989-06-12 1992-03-13 Rhone Poulenc Sante Use of compositions degradably by enzymatics for the coating of food additives for ruminants
DK161743C (en) * 1989-07-03 1992-02-17 Niro Atomizer As Procedure and apparatus for agglomeration of a powder-shaped material
EP0418596A3 (en) * 1989-09-21 1991-10-23 American Cyanamid Company Controlled release pharmaceutical compositions from spherical granules in tabletted oral dosage unit form
US5248516A (en) * 1989-12-19 1993-09-28 Fmc Corporation Film-forming composition: method of producing same and use for coating pharmaceuticals and foods and the like
IE66933B1 (en) * 1990-01-15 1996-02-07 Elan Corp Plc Controlled absorption naproxen formulation for once-daily administration
US5206030A (en) * 1990-02-26 1993-04-27 Fmc Corporation Film-forming composition and use for coating pharmaceuticals, foods and the like
JP2542122B2 (en) * 1990-04-18 1996-10-09 旭化成工業株式会社 Spherical nucleus, spherical granule and method for producing the same
DE59105613D1 (en) * 1990-08-24 1995-07-06 Spirig Ag Process for the production of pellets.
JP2669945B2 (en) * 1991-02-05 1997-10-29 ファナック株式会社 Profile control device
US5132142A (en) * 1991-03-19 1992-07-21 Glatt Gmbh Apparatus and method for producing pellets by layering power onto particles
CA2108575C (en) * 1991-04-16 2002-10-22 Kouichi Nakamichi Method of manufacturing solid dispersion
KR100221695B1 (en) * 1991-08-12 1999-09-15 그린 마틴, 브라이언 쥐 테슬리 Pharmaceutical spheroid formulation
US5215758A (en) * 1991-09-11 1993-06-01 Euroceltique, S.A. Controlled release matrix suppository for pharmaceuticals
US5266331A (en) 1991-11-27 1993-11-30 Euroceltique, S.A. Controlled release oxycodone compositions
US5656295A (en) * 1991-11-27 1997-08-12 Euro-Celtique, S.A. Controlled release oxycodone compositions
US5968551A (en) * 1991-12-24 1999-10-19 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
US5958459A (en) * 1991-12-24 1999-09-28 Purdue Pharma L.P. Opioid formulations having extended controlled released
US5681585A (en) * 1991-12-24 1997-10-28 Euro-Celtique, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US5273760A (en) 1991-12-24 1993-12-28 Euroceltigue, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US5286493A (en) 1992-01-27 1994-02-15 Euroceltique, S.A. Stabilized controlled release formulations having acrylic polymer coating
GB9202464D0 (en) * 1992-02-05 1992-03-18 Danbiosyst Uk Composition for nasal administration
SE9202250D0 (en) * 1992-07-29 1992-07-29 Gacell Lab Ab Controlled release morphine preparation
US5324351A (en) * 1992-08-13 1994-06-28 Euroceltique Aqueous dispersions of zein and preparation thereof
US5321012A (en) * 1993-01-28 1994-06-14 Virginia Commonwealth University Medical College Inhibiting the development of tolerance to and/or dependence on a narcotic addictive substance
CA2115792C (en) * 1993-03-05 2005-11-01 David J. Mayer Method for the treatment of pain
SE9301057L (en) * 1993-03-30 1994-10-01 Pharmacia Ab Controlled release preparation
US5849240A (en) * 1993-11-23 1998-12-15 Euro-Celtique, S.A. Method of preparing sustained release pharmaceutical compositions
US5891471A (en) * 1993-11-23 1999-04-06 Euro-Celtique, S.A. Pharmaceutical multiparticulates
IL110014A (en) * 1993-07-01 1999-11-30 Euro Celtique Sa Solid controlled-release oral dosage forms of opioid analgesics
US5879705A (en) * 1993-07-27 1999-03-09 Euro-Celtique S.A. Sustained release compositions of morphine and a method of preparing pharmaceutical compositions
DE4329794C2 (en) * 1993-09-03 1997-09-18 Gruenenthal Gmbh Tramadol salt-containing drugs with delayed release
US5500227A (en) * 1993-11-23 1996-03-19 Euro-Celtique, S.A. Immediate release tablet cores of insoluble drugs having sustained-release coating
US5478577A (en) * 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
US5411745A (en) * 1994-05-25 1995-05-02 Euro-Celtique, S.A. Powder-layered morphine sulfate formulations
US5460826A (en) * 1994-06-27 1995-10-24 Alza Corporation Morphine therapy
US5965161A (en) * 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
US5811126A (en) * 1995-10-02 1998-09-22 Euro-Celtique, S.A. Controlled release matrix for pharmaceuticals
US6419960B1 (en) * 1998-12-17 2002-07-16 Euro-Celtique S.A. Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations

Also Published As

Publication number Publication date
HU0303097D0 (en) 2003-11-28
EP1325746A1 (en) 2003-07-09
FI116658B (en) 2006-01-31
NO20041939L (en) 1993-05-27
DE69233699D1 (en) 2007-08-02
EP1258246B1 (en) 2004-03-17
HU224075B1 (en) 2005-05-30
EP1258246A2 (en) 2002-11-20
BR9205498A (en) 1994-06-07
DE69233691D1 (en) 2007-06-06
US20040096500A1 (en) 2004-05-20
EP1258246A3 (en) 2003-01-08
HU0400227D0 (en) 2004-04-28
HU0400226D0 (en) 2004-04-28
NO318890B1 (en) 2005-05-18
EP2106796A3 (en) 2009-11-04
RS50056B (en) 2008-11-28
EP2340833A3 (en) 2012-09-12
EP0722730B2 (en) 2013-08-07
EP2289517A3 (en) 2012-07-04
PT1327445E (en) 2004-07-30
US20060165792A1 (en) 2006-07-27
CN1245958C (en) 2006-03-22
DK1438959T3 (en) 2007-09-17
EP2289517A2 (en) 2011-03-02
AT261727T (en) 2004-04-15
NO307028B1 (en) 2000-01-31
PT1438959E (en) 2007-07-19
SK280295B6 (en) 1999-11-08
HUT69401A (en) 1995-09-28
PL172236B1 (en) 1997-08-29
WO1993010765A1 (en) 1993-06-10
RU2122411C1 (en) 1998-11-27
HU227516B1 (en) 2011-07-28
ES2286523T3 (en) 2007-12-01
HU227815B1 (en) 2012-03-28
PT1327446E (en) 2004-06-30
EP1327446B1 (en) 2004-03-17
YU49495B (en) 2006-08-17
DE69233326D1 (en) 2004-04-22
ZA9209227B (en) 1993-07-12
CA2098738C (en) 1999-08-17
HU227514B1 (en) 2011-07-28
CZ292849B6 (en) 2003-12-17
DK0722730T3 (en) 2002-11-25
US20020018810A1 (en) 2002-02-14
CN1364458A (en) 2002-08-21
BG97973A (en) 1994-05-27
DE69233328T3 (en) 2008-02-07
DK200000364U3 (en) 2001-03-23
ES2186737T3 (en) 2003-05-16
FI20031891A (en) 2003-12-22
NO932661D0 (en) 1993-07-23
DK0576643T5 (en) 2004-11-22
HU0400225D0 (en) 2004-04-28
US20060165791A1 (en) 2006-07-27
AU657027B2 (en) 1995-02-23
PL173574B1 (en) 1998-03-31
FI118251B1 (en)
PT1258246E (en) 2004-06-30
FI933330A (en) 1993-07-23
HK1058474A1 (en) 2007-02-23
PT722730E (en) 2003-03-31
DE69233326T2 (en) 2005-03-10
DE69233327T2 (en) 2005-03-10
CZ286913B6 (en) 2000-08-16
EP0722730B1 (en) 2002-10-30
EP0576643A4 (en) 1994-03-18
EP2106797A3 (en) 2009-11-04
DK1258246T3 (en) 2004-07-05
EP1438959B1 (en) 2007-04-25
AT332691T (en) 2006-08-15
SK92293A3 (en) 1994-04-06
AT360421T (en) 2007-05-15
DE69233328T2 (en) 2005-03-10
FI118251B (en) 2007-09-14
CZ300183B6 (en) 2009-03-11
EP1327446A1 (en) 2003-07-16
RS50055B (en) 2008-11-28
DE69232837D1 (en) 2002-12-05
AT261726T (en) 2004-04-15
IL103909A (en) 1996-09-12
BG61753B1 (en) 1998-05-29
FI20031890A (en) 2003-12-22
FI118252B1 (en)
NO996447L (en) 1993-09-24
EP1327445B1 (en) 2004-03-17
EP1810679A2 (en) 2007-07-25
ES2215983T3 (en) 2004-10-16
EP1327446B2 (en) 2007-08-22
DK0722730T4 (en) 2013-11-18
EP1438959A1 (en) 2004-07-21
US20060057210A1 (en) 2006-03-16
DE69233328D1 (en) 2004-04-22
EP0576643B1 (en) 1996-10-23
DE69214802D1 (en) 1996-11-28
EP2106796A2 (en) 2009-10-07
HU227518B1 (en) 2011-07-28
EP2243484A3 (en) 2012-01-11
HK1059209A1 (en) 2004-12-17
DE69233778D1 (en) 2010-02-25
EP1325746B1 (en) 2006-07-12
DK0722730T5 (en) 2003-03-31
EP2289517B1 (en) 2014-05-07
HU227515B1 (en) 2011-07-28
HU227517B1 (en) 2011-07-28
DE69233691T2 (en) 2008-01-24
EP1774969A3 (en) 2007-10-03
EP1810679A3 (en) 2007-10-03
EP2340833A2 (en) 2011-07-06
PT1325746E (en) 2006-11-30
DE69233640D1 (en) 2006-08-24
MX9302968A (en) 1994-05-31
FI113152B1 (en)
DE69214802T2 (en) 1997-05-07
JP4016074B2 (en) 2007-12-05
PH31679A (en) 1999-01-18
EP1810679B1 (en) 2010-01-06
NO20041667L (en) 1993-09-24
HK1073255A1 (en) 2008-01-25
HU0400357D0 (en) 2004-04-28
HU0400224D0 (en) 2004-04-28
CZ176493A3 (en) 1994-04-13
DE69233640T2 (en) 2007-06-14
EP0576643A1 (en) 1994-01-05
NO996447D0 (en) 1999-12-23
US20040185098A1 (en) 2004-09-23
AU3147693A (en) 1993-06-28
EP2106797A2 (en) 2009-10-07
EP1774969A2 (en) 2007-04-18
US20060099255A1 (en) 2006-05-11
CN1087262A (en) 1994-06-01
FI20031889A (en) 2003-12-22
AT144418T (en) 1996-11-15
US5508042A (en) 1996-04-16
HK1068004A1 (en) 2007-10-12
HU226929B1 (en) 2010-03-01
DK1327446T3 (en) 2004-08-02
EP1502592A1 (en) 2005-02-02
GR3022273T3 (en) 1997-04-30
AT454150T (en) 2010-01-15
DK1325746T3 (en) 2006-11-06
PT1502592E (en) 2007-09-17
CZ298499B6 (en) 2007-10-17
DK1327445T3 (en) 2004-07-26
EP0722730A1 (en) 1996-07-24
EP1502592B1 (en) 2007-06-20
DE9219234U1 (en) 2001-03-29
DE69232837T3 (en) 2014-01-02
ES2186737T5 (en) 2014-01-17
HU9301517D0 (en) 1993-09-28
FI933330A0 (en) 1993-07-23
FI113152B (en) 2004-03-15
FI118250B1 (en)
ES2096781T3 (en) 1997-03-16
NO325483B1 (en) 2008-05-13
NO323334B1 (en) 2007-03-26
PT1810679E (en) 2010-02-18
FI20031888A (en) 2003-12-22
ES2213720T3 (en) 2004-09-01
AT261725T (en) 2004-04-15
HK1059210A1 (en) 2004-12-17
US5266331A (en) 1993-11-30
RS50054B (en) 2008-11-28
EP2243484A2 (en) 2010-10-27
YU35893A (en) 1997-03-07
NO322378B1 (en) 2006-09-25
US20010008639A1 (en) 2001-07-19
US20030099704A1 (en) 2003-05-29
ES2215984T5 (en) 2008-03-16
DE69233699T2 (en) 2008-02-28
US20040105887A1 (en) 2004-06-03
HU228058B1 (en) 2012-09-28
NO20043264L (en) 1993-09-24
JPH06507645A (en) 1994-09-01
FI116658B1 (en)
FI118250B (en) 2007-09-14
DK1327446T4 (en) 2007-12-17
US5549912A (en) 1996-08-27
CN1165307C (en) 2004-09-08
JP3375960B2 (en) 2003-02-10
HK1051803A1 (en) 2005-03-04
DE69232837T2 (en) 2003-06-18
AT226822T (en) 2002-11-15
FI933330D0 (en)
ES2287625T3 (en) 2007-12-16
IL103909D0 (en) 1993-04-04
AT365041T (en) 2007-07-15
ES2215984T3 (en) 2004-10-16
DK0576643T3 (en) 1997-04-21
FI118252B (en) 2007-09-14
HU0302920D0 (en) 2003-11-28
JP2002370983A (en) 2002-12-24
NO20041662L (en) 1993-09-24
NO307028B3 (en) 2009-05-25
EP1327445A1 (en) 2003-07-16
ES2339392T3 (en) 2010-05-19
DK1810679T3 (en) 2010-02-08
DE69233327D1 (en) 2004-04-22
HU0401532D0 (en) 2004-09-28
ES2268189T3 (en) 2007-03-16
DK1502592T3 (en) 2007-10-22
RO115112B1 (en) 1999-11-30
NO932661L (en) 1993-09-24

Similar Documents

Publication Publication Date Title
Christensen et al. The reflex dystrophy syndrome response to treatment with systemic corticosteroids.
CA2328730C (en) Treatment of iatrogenic and age-related hypertension and pharmaceutical compositions useful therein
KR0164435B1 (en) A pharmaceutical composition for the treatment of obesity
AU593051B2 (en) Method of treating alzheimer's disease
RU2314810C2 (en) Method for treatment using medicinal formulations containing pharmaceutical compositions of 5,8,14,-triazatetracyclo[10.3.1.0 (2,11).0(4,9)]hexadeca-2( 11),3,5,7,9-pentaene
CA2221356C (en) Treatment of inflammatory bowel disease using oral dosage forms of omega-3 polyunsaturated acids
JP3924321B2 (en) Pain reducing pharmaceutical composition and pain reducing method
Ilias et al. Pain control after hysterectomy: an observer-blind, randomised trial of lornoxicam versus tramadol.
Abelin et al. Effectiveness of a transdermal nicotine system in smoking cessation studies.
EP0735863B1 (en) Accelerated release composition containing bromocriptine
USRE39480E1 (en) Chromium/biotin treatment of type II diabetes
CY1112260T1 (en) Controlled release formulation of hydrocodone
RO115780B1 (en) Synergistic combination
Glorioso et al. Double-blind multicentre study of the activity of S-adenosylmethionine in hip and knee osteoarthritis.
EP1570823A3 (en) Substained analgesia achieved with buprenorphine
NO961136L (en) Pharmaceutical formulation basis for nano-suspensions
EP1275381A4 (en) Time-release coated solid compositions for oral administration
EP1243269A3 (en) Opioid formulations having extended controlled release
US4446140A (en) Method and composition for treating mouth pain
Burkert Clinical overview of mesna.
AP9400645A0 (en) Thermal infusion process for preparing controlled release solid dosage forms of medicaments for oral administration and controlled release sold dosage forms of medicaments prepared thereby.
MX9504034A (en) Medical administering forms containing tioctic acid, or tioctic acid solid salts having improved release and bioavailability.
ES2035821T3 (en) Integrated directed administration system.
HUT73976A (en) Sustained-release opioid formulations for treating pain
NZ532491A (en) Oral pharmaceutical products containing 17beta-estradiol-3-lower alkanoate, method of administering the same and process of preparation

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry